Primmune Therapeutics

1 Follower


Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.

Richard Daniels
Chief Operating Officer
Paulo Rangel
Chief Business Officer & Co-Founder
James Appleman
SVP, R&D & CSO Co-Founder, Director
Scott Zook
Senior Vice President Global Manufacturing
Stephen E. Webber
VP, Medicinal Chemistry, & Co-Founder

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.